English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Department of Medical and Experimental Oncology, Heliodor Święcicki Clinical Hospital, Poznan, Poland; Department of Biology and Environmental Studies, Department of Diagnostics and Cancer Immunology, Greater Poland Cancer Center, Chair of Medical Biotechnology, Poznan University of Medical Sciences, Poznan, Poland; Biocontract, Poznan, Poland Correspondence to: Jacek Mackiewicz. Department of Medical and Experimental Oncology, Heliodor Święcicki Clinical Hospital, Poznań, Poland. Email: jmackiewicz@ump.edu.pl. Provenance: This is an invited article commissioned by the Editorial Office, Annals of Translational Medicine. Comment on: Eggermont AMM, Blank CU, Mandala M, et al. Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/ KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma. Eur J Cancer 2019;116:148-57.

Is AJCC 8th Edition useful in qualifying melanoma patients to adjuvant therapy?